These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 19792961

  • 1. Satraplatin for the therapy of castration-resistant prostate cancer.
    Sonpavde G, Sternberg CN.
    Future Oncol; 2009 Sep; 5(7):931-40. PubMed ID: 19792961
    [Abstract] [Full Text] [Related]

  • 2. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
    Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, Eymard JC, Falcon S, Calabrò F, James N, Bodrogi I, Harper P, Wirth M, Berry W, Petrone ME, McKearn TJ, Noursalehi M, George M, Rozencweig M.
    J Clin Oncol; 2009 Nov 10; 27(32):5431-8. PubMed ID: 19805692
    [Abstract] [Full Text] [Related]

  • 3. Satraplatin: BMS 182751, BMY 45594, JM 216.
    Drugs R D; 2007 Nov 10; 8(2):125-32. PubMed ID: 17324011
    [Abstract] [Full Text] [Related]

  • 4. Current status and future prospects for satraplatin, an oral platinum analogue.
    Choy H, Park C, Yao M.
    Clin Cancer Res; 2008 Mar 15; 14(6):1633-8. PubMed ID: 18347164
    [Abstract] [Full Text] [Related]

  • 5. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
    Oh WK, Tay MH, Huang J.
    Cancer; 2007 Feb 01; 109(3):477-86. PubMed ID: 17186531
    [Abstract] [Full Text] [Related]

  • 6. Satraplatin: an orally available platinum analog for the treatment of cancer.
    Choy H.
    Expert Rev Anticancer Ther; 2006 Jul 01; 6(7):973-82. PubMed ID: 16831070
    [Abstract] [Full Text] [Related]

  • 7. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.
    Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, Van Erps P, Theodore C, Koriakine O, Oliver T, Lebwohl D, Debois M, Zurlo A, Collette L, Genitourinary Tract Group of the EORTC.
    Oncology; 2005 Jul 01; 68(1):2-9. PubMed ID: 15741753
    [Abstract] [Full Text] [Related]

  • 8. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W, Eisenberger M.
    Oncologist; 2005 Jul 01; 10 Suppl 3():30-9. PubMed ID: 16368869
    [Abstract] [Full Text] [Related]

  • 9. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
    Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF.
    Clin Genitourin Cancer; 2011 Sep 01; 9(1):27-30. PubMed ID: 21700509
    [Abstract] [Full Text] [Related]

  • 10. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
    Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P.
    BJU Int; 2010 Oct 01; 106(7):974-8. PubMed ID: 20230389
    [Abstract] [Full Text] [Related]

  • 11. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K, Lamphere L, Unteregger G, Jung V, Kaplan F, Xu JP, Rattel B, Caligiuri M.
    Cancer Chemother Pharmacol; 2007 Sep 01; 60(4):589-600. PubMed ID: 17541592
    [Abstract] [Full Text] [Related]

  • 12. Zibotentan for the treatment of castrate-resistant prostate cancer.
    Shepard DR, Dreicer R.
    Expert Opin Investig Drugs; 2010 Jul 01; 19(7):899-908. PubMed ID: 20497097
    [Abstract] [Full Text] [Related]

  • 13. Clinical and pharmacokinetic evaluation of satraplatin.
    Doshi G, Sonpavde G, Sternberg CN.
    Expert Opin Drug Metab Toxicol; 2012 Jan 01; 8(1):103-11. PubMed ID: 22098065
    [Abstract] [Full Text] [Related]

  • 14. Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.
    Parente P, Parnis F, Gurney H.
    Asia Pac J Clin Oncol; 2012 Mar 01; 8(1):31-42. PubMed ID: 22369442
    [Abstract] [Full Text] [Related]

  • 15. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR, Hussain MH.
    Curr Opin Oncol; 2013 May 01; 25(3):252-60. PubMed ID: 23511665
    [Abstract] [Full Text] [Related]

  • 16. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.
    Beardsley EK, Chi KN.
    Curr Opin Support Palliat Care; 2008 Sep 01; 2(3):161-6. PubMed ID: 18685415
    [Abstract] [Full Text] [Related]

  • 17. Novel chemotherapies in development for management of castration-resistant prostate cancer.
    Tewari AK, George DJ.
    Curr Opin Urol; 2013 May 01; 23(3):220-9. PubMed ID: 23511791
    [Abstract] [Full Text] [Related]

  • 18. Future directions in the treatment of androgen-independent prostate cancer.
    Petrylak DP.
    Urology; 2005 Jun 01; 65(6 Suppl):8-12. PubMed ID: 15939077
    [Abstract] [Full Text] [Related]

  • 19. Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation.
    McKeage MJ.
    Drugs; 2007 Jun 01; 67(6):859-69. PubMed ID: 17428104
    [Abstract] [Full Text] [Related]

  • 20. The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
    Rawlinson A, Mohammed A, Beatty J, Bell R, Miller M.
    Expert Rev Anticancer Ther; 2012 Apr 01; 12(4):429-37. PubMed ID: 22500680
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.